-Advertisement-
-Advertisement-
Alagille Syndrome

FDA label expansion makes maralixibat available for infants 3 months and older with ALGS
The U.S. Food and Drug Administration approved a reduction in age from 1 year to 3 months for maralixibat (Livmarli; Mirum) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS), according to a press release. The label expansion was based on data from the RISE...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 MedJournal 360® is a trademark of International Healthcare Media, LLC. All rights Reserved